Results

1–10 of 69 results for Wet AMD

Treatment Burden and Vision Analysis of Anti-VEGF Therapies for the Treatment of Neovascular AMD
Rahul Komati, MD
Annual Meeting Talks
2020
Predicting Long-term Response to Ranibizumab After Three Injections in Patients With Age-Related Macular Degeneration
Paul Hahn, MD, PhD, FASRS
Annual Meeting Talks
2020
Two-Year Results From the Subretinal RGX-314 Gene Therapy Phase 1/2a Study for the Treatment of Neovascular AMD
Robert L. Avery, MD
Updates from the Field
2021
Ziv-aflibercept Efficacy in Better Regulating Neovascular AMD (ZEBRA) Trial
Kapil G. Kapoor, MD
On Demand Cases, Courses, and Papers
2019
Treatment course and outcomes of neovascular age-related macular degeneration in patients receiving intraocular pressure-lowering drops
Bobeck S Modjtahedi, MD
On Demand Cases, Courses, and Papers
2019
Real World Patient and Clinical Characteristics in Treatment Naive Neovascular Age-Related Macular Degeneration
Matthew P. Ohr, MD
On Demand Cases, Courses, and Papers
2019
PRN cycles of three monthly anti-VEGF injections in neovascular AMD: 12 and 24 months results.
Touka Banaee, MD
On Demand Cases, Courses, and Papers
2019
It’s the Patient, Not the Agent: An Assessment of Anti-VEGF Extended Dosing Intervals in Patients With nAMD
David A. Eichenbaum, MD, FASRS
On Demand Cases, Courses, and Papers
2019
Intravitreal Bevacizumab vs. Bevacizumab with Dexamethasone for the Treatment of Exudative Age-Related Macular Degeneration
Reda Issa, MD
On Demand Cases, Courses, and Papers
2019
Does Anti-VEGF Therapy Affect the Rate of Expansion of Geographic Atrophy in Patients with Neovascular AMD Managed by a Treat-Extend-Stop Protocol?
Sean David Adrean, MD, FAAO, FASRS
On Demand Cases, Courses, and Papers
2019